体外诊断 (IVD) 趋势与市场趋势 (2025)

In Vitro Diagnostic (IVD) Trends and Market Update, 2025

出版日期: 2025年12月02日 | 出版商:

Kalorama Information | 英文 98 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

Kalorama Information 发布的 "体外诊断 (IVD) 趋势与市场趋势 (2025)" 报告深入分析了在全球经济不确定性背景下不断发展的 IVD 市场。该报告每年发布两次（4 月和 12 月），紧接着 Kalorama 的旗舰研究报告 "全球体外诊断 (IVD) 市场，第 18 版" 之后，既是独立的资讯来源，也是诊断产业决策者的策略补充。

在技术创新和不断增长的医疗需求的推动下，2025 年 IVD 市场将继续保持成长势头。下一代定序 (NGS)、微流控技术和精准医疗的创新正在变革诊断方式，使癌症和遗传疾病等复杂疾病的检测能够实现高度精确、灵敏和个人化。伴随诊断和多重检测的普及凸显了以患者为中心的医疗模式和对疾病更深入理解的趋势。

吸引业界关注的关键成长领域包括即时检测、癌症诊断、伴随诊断技术、免疫化学和质谱分析。核酸检测、基因检测和HPV分子诊断预计将大幅成长，并将塑造体外诊断的未来。

本报告提供以下方面的实用见解：

市场推动因素与关键产业趋势
新产品开发引领创新
竞争格局与主要参与者策略
新兴机会与高成长领域

基于专家分析和最新数据，Kalorama为企业高管、行业领导者和投资者提供工具，帮助他们应对监管挑战、利用技术进步并在充满活力的体外诊断领域中识别盈利机会。

Kalorama Information's In Vitro Diagnostic (IVD) Trends and Market Update, 2025 delivers critical insights into the evolving IVD market amid global economic uncertainties. Published twice annually-in April and in December following the release of Kalorama's flagship study, The Worldwide Market for In Vitro Diagnostics (IVD), 18th Edition-this report serves as both a standalone resource and a strategic companion for decision-makers in the diagnostics industry.

The 2025 IVD market continues its growth trajectory, fueled by technological breakthroughs and rising healthcare demands. Innovations in next-generation sequencing (NGS), microfluidics, and precision medicine are transforming diagnostics, enabling highly accurate, sensitive, and personalized testing for complex conditions such as cancer and genetic disorders. The surge in companion diagnostics and multiplex testing underscores a shift toward patient-centric care and deeper disease insights.

Key growth segments attracting industry attention include Point-of-Care testing, cancer diagnostics, companion diagnostics technologies, immunochemistry, and mass spectrometry. Nucleic acid assays, gene testing, and HPV molecular diagnostics are poised for significant expansion, shaping the future of IVD.

This report provides actionable intelligence on:

Market drivers and major industry trends
New product developments shaping innovation
Competitive landscape and key player strategies
Emerging opportunities and high-growth segments

With expert analysis and up-to-date data, Kalorama equips executives, industry leaders, and investors with the tools to navigate regulatory challenges, capitalize on technological advancements, and identify profitable opportunities in the dynamic IVD sector.

Chapter 1: Worldwide IVD Market - December 2025 Update

About Kalorama Information
IVD Market Demand and Growth
- Figure 1-1: Q1-Q3 IVD Segment Performance Commentary, 2025 [Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology (Molecular), Point-of-Care (POC)]
- Table 1-1: Global In Vitro Diagnostic Sales by Product Market, 2025 ($ million) [Blood Bank Molecular - NAT Screens; Blood Grouping/Typing; Circulating Tumor Cells; Clinical Chemistry; Coagulation (PT/INR); Coagulation, Molecular; D-dimer; Diabetes HbA1c, lab; Drugs of Abuse; Hematology - Core Lab; Histology/Cytology; HPV, Molecular; Immuno - Blood Bank Screening; Immuno-Infectious Disease; Immunoassays - Non-isotopic; Mass Spectrometry; Microbiology (ID/AST); Microbiology (Molecular); Microbiology - Mass Spectrometry; NAAT - Oncology; Nucleic Acid Assays - Genetic/Inherited; Other Immunos; POC, OTC Diabetes; POC, OTC Other; POC, Professional/Hospital]
- Figure 1-2: IVD Segment Performance, Q1 2025-Q4 2025 estimated ($ million) [Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, Point-of-Care (POC), Other]
- Figure 1-3: IVD Segment Performance, Total Market Value, 2025 estimated ($ million) [Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, Point-of-Care (POC), Other]
- COVID-19 Diagnostic Markets
  - Table 1-2: COVID-19 Product Sales, 2025 ($ million) [Immunoassay (Antigen, Serology), Molecular, Rapid]
Effect of COVID-19 on Market Segments
- Table 1-3: IVD Market excluding and including COVID-19, 2025 ($ million)
- Figure 1-4: IVD Market Distribution, by Segment, 2025 (%) [COVID-19 Assays and Instruments, IVD Market excluding COVID-19 Assays and Instruments]
- Figure 1-5: IVD Market by COVID-19 and non-COVID markets, Quarterly Performance, 2025 estimated ($ million)
- Table 1-4: Global In Vitro Diagnostic Market - YoY Growth, 2024-2025 (%) [Blood Bank Molecular - NAT Screens, Blood Grouping/Typing, Circulating Tumor Cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, Molecular, D-dimer, Diabetes HbA1c, Lab, Drugs of Abuse, Hematology - Core Lab, Histology/Cytology, HPV, Molecular, Immuno - Blood Bank Screening, Immuno - Infectious Disease, Immunoassays- non-isotopic, Microbiology (ID/AST), Microbiology (Molecular), Microbiology - Mass Spectrometry, NAAT - Oncology, Nucleic Acid Assays - Genetic/Inherited, Other Immunos, POC, OTC Diabetes, POC, OTC Other, POC, Professional/Hospital]
- Figure 1-6: Global In Vitro Diagnostic Market - YoY Growth 2024-2025 (%) [Blood Bank Molecular - NAT Screens, Blood Grouping/Typing, Circulating Tumor Cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, Molecular, D-dimer, Diabetes HbA1c, Lab, Drugs of Abuse, Hematology - Core Lab, Histology/Cytology, HPV, Molecular, Immuno - Blood Bank Screening, Immuno - Infectious Disease, Immunoassays- non-isotopic, Microbiology (ID/AST), Microbiology (Molecular), Microbiology - Mass Spectrometry, NAAT - Oncology, Nucleic Acid Assays - Genetic/Inherited, Other Immunos, POC, OTC Diabetes, POC, OTC Other, POC, Professional/Hospital

Chapter 2: Product Trends and New Developments

Selected New - Q3 2025 - Core IVD Product Launches, Developments and Trends
- Immunoassay
- Mass Spectrometry
- Molecular
- Personalized Medicine
- POC
- Coagulation
- Flow Cytometry
- Sequencing
Selected COVID-19 Developments - Q3 2025
- Antigen/Antibody
- Molecular

Chapter 3: Top IVD Market Participant Results

Selected Competitive Leader Updates
- Figure 3-1: IVD Segment Growth by Leading Competitors, Change in Sales 2024-2025 (%)
- Figure 3-2: Changes in Market Distribution for IVD Sales, 2022-2025 estimated (%)
- Figure 3-3: Comparison of Total Diagnostic Sales for Abbott vs Roche, 2023-2025 estimated ($ million)
Q3 2025 M&A Activity
- Table 3-1: Q3 2025 Merger and Acquisition Activity
Abbott Laboratories
- Table 3-2: Abbott Corporate Summary
Becton Dickinson and Co
- Table 3-3: Becton Dickinson Corporate Summary
bioMerieux SA
- Table 3-4: bioMerieux Corporate Summary
Danaher Corporation
- Table 3-5: Danaher Corporation Summary
Dexcom, Inc
- Table 3-6: Dexcom Corporate Summary
Exact Sciences
- Table 3-7: Exact Sciences Corporate Summary
Roche Diagnostic
- Table 3-8: Roche Diagnostic Corporate Summary
Siemens Healthineers
- Table 3-9: Siemens Healthineers Corporate Summary
Sysmex Corporation
- Table 3-10: Sysmex Corporate Summary
Thermo Fisher Scientific
- Table 3-11: Thermo Fisher Scientific Corporate Summary